In the third largest M&A deal of 2020 so far, Bristol Myers Squibb (BMS) has agreed to acquire MyoKardia for US$13.1 B. With the deal, BMS gains access to mavacamten, a Phase III candidate for the treatment of obstructive hypertrophic cardiomyopathy for which MyoKardia plans to submit a regulatory filing to the FDA in the first quarter of 2021; mavacamten will complement BMS’ existing cardiovascular portfolio, which is led by Eliquis® (apixaban). Interestingly, the deal comes less than two years after Sanofi terminated its agreement with MyoKardia to jointly develop three of its programmes, including mavacamten.